212712-42-0

Basic information

• Product Name: 2-Oxazolidinone, 3-[3-(1,3-benzodioxol-5-yl)-1-oxopropyl]-4-(phenylmethyl)-, (4S)-
• CAS NO: 212712-42-0
• Molecular Formula: C20H19NO5
• Molecular Weight: 353.375
• Mol File: 212712-42-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 3-[3-(1,3-benzodioxol-5-yl)-1-oxopropyl]-4-(phenylmethyl)-, (4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 3-[3-(1,3-benzodioxol-5-yl)-1-oxopropyl]-4-(phenylmethyl)-, (4S)-(212712-42-0)
• EPA Substance Registry System: 2-Oxazolidinone, 3-[3-(1,3-benzodioxol-5-yl)-1-oxopropyl]-4-(phenylmethyl)-, (4S)-(212712-42-0)

Safety Data

• Hazardous Substances Data: 212712-42-0(Hazardous Substances Data)

Upstream product

• 2815-95-4 3-(1,3 benzodioxol-5-yl)propionic acid 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 7116-48-5 3-benzo[1,3]dioxol-5-yl-propionic acid ethyl ester 
• 120-57-0 piperonal 
• 24393-66-6 ethyl (E)-3-(benzo[d][1,3]dioxol-5-yl)acrylate 
• 2373-80-0 3,4-(methylenedioxy)cinnamic acid 
• 68996-81-6 3-benzo[1,3]dioxol-5-yl-propionyl chloride 

Downstream Products

• 647029-32-1 1-tert-butyldimethylsilyloxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyn-3-ol 
• 647029-34-3 (2R)-1-tert-butyldimethylsilyloxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyn-3-one 
• 647008-08-0 (2S,3R)-3-hydroxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxybenzyl)-3-(1-methylethyl)-4-pentynoic acid 
• 647029-39-8 (2S,3S)-3-hydroxy-3-isopropyl-5-(4-methoxyphenyl)-2-(3,4-methylenedioxybenzyl)-4-pentynoic acid 
• 647008-04-6 (2R,3R)-5-(4-methoxyphenyl)-2-(3,4-methylenedioxybenzyl)-3-(1-methylethyl)-4-pentyne-1,3-diol 
• 647008-05-7 (2R,3S)-5-(4-methoxyphenyl)-2-(3,4-methylenedioxybenzyl)-3-(1-methylethyl)-4-pentyne-1,3-diol 
• 647029-28-5 5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyne-1,3-diol 
• 647029-41-2 5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyne-1,3-diol 
• 647029-29-6 5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyne-1,3-diol 
• 647029-45-6 (2S,3S)-2-Benzo[1,3]dioxol-5-ylmethyl-3-hydroxy-3-isopropyl-5-(4-methoxy-phenyl)-pent-4-ynal 
• 647029-36-5 (2R)-1-hydroxy-5-(4-methoxyphenyl)-2-(3,4-methylenedioxyphenyl)methyl-4-pentyn-3-one 
• 647007-87-2 (4S)-4-benzyl-1-[(2S,3R)-3-hydroxy-4-methyl-2-(3,4-methylenedioxybenzyl)valeryl]-2-oxazolidinone 
• 647007-89-4 (4S)-4-benzyl-1-[(2R,3R)-3-hydroxy-4-methyl-2-(3,4-methylenedioxybenzyl)valeryl]-2-oxazolidinone 
• 647008-14-8 (4S)-4-benzyl-1-[(2R,3S)-3-hydroxy-4-methyl-2-(3,4-methylenedioxybenzyl)valeryl]-2-oxazolidinone 

Relevant articles and documents

Synthesis method and application of cubebin

The invention discloses a synthesis method of cubebin, which comprises the following steps: using 1,3-benzodioxole-5-carboxaldehyde and malonic acid as initial raw materials to generate 1,3-benzodioxole-5-propanoic acid, reacting the 1,3-benzodioxole-5-propanoic acid with oxalyl chloride to generate 1,3-benzodioxole-5-propionyl chloride, then reacting the 1,3-benzodioxole-5-propionyl chloride with (S)-4-benzyl-2-oxazolidinone to generate corresponding amide, reacting a product with bromopropyl to generate corresponding olefin, generating a corresponding carbonyl compound under the catalysis of a combined oxidant OsO4/NMO, using the carbonyl compound to prepare a corresponding hydroxyl compound, oxidizing the hydroxyl compound into a lactone compound by using a Fetizon reagent, reacting the lactone compound with 5-(bromomethyl)-1,3-benzodioxole, and finally, reducing the product by using diisobutylaluminium hydride to obtain cubebin. The invention further discloses application of cubebin in sedative and peaceful sleep. The invention provides a potential therapeutic drug for calming and sleeping.

Systematic strategy for the synthesis of cyanobacterin and its stereoisomers. 1. Asymmetric total synthesis of dechloro-cyanobacterin and its enantiomer

The stereocontrolled total synthesis of the non-chlorinated analog of cyanobacterin, a potent photosynthesis inhibitor, was achieved by 12 steps in a 10.0% overall yield. Its enantiomer was also synthesized from the same starting material. This synthetic strategy is expected to be applicable to prepare cyanobacterin and all its stereoisomers, together with other similar bioactive compounds.